Business
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing
About this update from Eyepoint, Inc.
WATERTOWN, Mass. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936 . A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com . A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States , and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex- U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program. Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts . Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China , Macao , Hong Kong and Taiwan . DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. Investors: Christina Tartaglia Precision AQDirect: 212-698-8700 [email protected] Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 [email protected] Source: EyePoint Pharmaceuticals, Inc.